• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.50 岁人群中接种双联流感和肺炎球菌疫苗的成本效益分析。
Vaccine. 2010 Nov 10;28(48):7620-5. doi: 10.1016/j.vaccine.2010.09.053. Epub 2010 Sep 29.
2
Cost-effectiveness of pneumococcal and influenza vaccination standing order programs.肺炎球菌和流感疫苗接种常规程序的成本效益。
Am J Manag Care. 2013 Jan 1;19(1):e30-7.
3
Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.18-64 岁高危成年人疫苗接种率提高的成本效益：基于模型的决策分析。
BMC Infect Dis. 2018 Jan 25;18(1):52. doi: 10.1186/s12879-018-2967-2.
4
Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis.50 岁人群中肺炎球菌疫苗接种策略以减少种族差异：美国社会视角下的成本效益分析。
Value Health. 2024 Jun;27(6):721-729. doi: 10.1016/j.jval.2024.02.021. Epub 2024 Mar 8.
5
Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.美国老年人肺炎球菌疫苗接种的成本效益以及提高接种率的项目的变化。
J Am Geriatr Soc. 2024 Aug;72(8):2423-2433. doi: 10.1111/jgs.19031. Epub 2024 Jun 1.
6
Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.“四支柱实践转型计划”提高65岁及以上成年人疫苗接种率的成本效益分析
J Am Geriatr Soc. 2017 Apr;65(4):763-768. doi: 10.1111/jgs.14588. Epub 2016 Dec 26.
7
Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. Populations.65 岁及以上老年人的肺炎球菌疫苗接种：美国人群的成本效益和健康影响。
Am J Prev Med. 2020 Apr;58(4):487-495. doi: 10.1016/j.amepre.2019.10.022. Epub 2020 Jan 28.
8
Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.肺炎球菌结合疫苗在免疫功能低下成人中的成本效益。
Vaccine. 2013 Aug 20;31(37):3950-6. doi: 10.1016/j.vaccine.2013.06.037. Epub 2013 Jun 24.
9
Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.对香港长期护理机构老年人进行流感和肺炎球菌疫苗接种的成本效益分析。
J Epidemiol Community Health. 2009 Nov;63(11):906-11. doi: 10.1136/jech.2008.081885. Epub 2009 Jul 15.
10
Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic.流感大流行期间医护人员接种肺炎球菌多糖疫苗的成本效益。
Am J Manag Care. 2010 Mar;16(3):200-6.

引用本文的文献

1
The immunogenicity and safety of an inactivated quadrivalent influenza vaccine and a 23-valent pneumococcal polysaccharide vaccine in individuals with chronic diseases.一种灭活四价流感疫苗和一种23价肺炎球菌多糖疫苗在慢性病患者中的免疫原性和安全性。
Front Immunol. 2025 Aug 1;16:1624095. doi: 10.3389/fimmu.2025.1624095. eCollection 2025.
2
Evaluating Free PPV23 Vaccination for the Elderly in Nanning, China: A Cost-Effectiveness Analysis.评估中国南宁市老年人免费接种23价肺炎球菌多糖疫苗：一项成本效益分析。
Vaccines (Basel). 2025 Jul 18;13(7):763. doi: 10.3390/vaccines13070763.
3
Health and Economic Impact of COVID-19 Surveillance Testing in Seattle Homeless Shelters: A Cost-Effectiveness Analysis.西雅图无家可归者收容所中新冠病毒监测检测的健康与经济影响：一项成本效益分析
AJPM Focus. 2024 Dec 5;4(2):100307. doi: 10.1016/j.focus.2024.100307. eCollection 2025 Apr.
4
Optimization of Elderly Influenza and Pneumococcal Immunization Programs in Beijing, China Using Health Economic Evaluations: A Modeling Study.利用卫生经济评估优化中国北京老年人流感和肺炎球菌免疫规划：一项建模研究
Vaccines (Basel). 2023 Jan 11;11(1):161. doi: 10.3390/vaccines11010161.
5
Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review.季节性流感疫苗经济评估中安全相关问题的纳入：一项系统综述。
Vaccines (Basel). 2021 Feb 2;9(2):111. doi: 10.3390/vaccines9020111.
6
The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.降低严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染传染期的价值。
PLoS Comput Biol. 2021 Jan 7;17(1):e1008470. doi: 10.1371/journal.pcbi.1008470. eCollection 2021 Jan.
7
Lowering the recommended age for the free and active offer of influenza vaccination in Italy: clinical and economic impact analysis in the Liguria region.降低意大利免费主动提供流感疫苗的建议年龄：利古里亚地区的临床和经济影响分析。
Hum Vaccin Immunother. 2021 May 4;17(5):1387-1395. doi: 10.1080/21645515.2020.1810494. Epub 2020 Oct 29.
8
Vaccination coverage with the pneumococcal and influenza vaccine among persons with chronic diseases in Shanghai, China, 2017.2017 年中国上海慢性病患者的肺炎球菌疫苗和流感疫苗接种率。
BMC Public Health. 2020 Mar 19;20(1):359. doi: 10.1186/s12889-020-8388-3.
9
Cost-effectiveness of adult vaccinations: A systematic review.成人疫苗接种的成本效益：系统评价。
Vaccine. 2019 Jan 7;37(2):226-234. doi: 10.1016/j.vaccine.2018.11.056. Epub 2018 Dec 4.
10
Epidemiologic and economic impact of pharmacies as vaccination locations during an influenza epidemic.流感大流行期间，将药店作为疫苗接种点的流行病学和经济学影响。
Vaccine. 2018 Nov 12;36(46):7054-7063. doi: 10.1016/j.vaccine.2018.09.040. Epub 2018 Oct 16.

本文引用的文献

1
Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.在中老年人群中，进行肺炎球菌多糖疫苗初次接种或加强免疫后，其安全性和抗体应答情况，包括 5 年的抗体持久性。
J Infect Dis. 2010 Feb 15;201(4):516-24. doi: 10.1086/649839.
2
Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years.接种 23 价肺炎球菌多糖疫苗可诱导 65 岁及以上老年人产生高水平和持久的功能性抗体应答。
J Infect Dis. 2010 Feb 15;201(4):525-33. doi: 10.1086/651131.
3
A computer simulation of employee vaccination to mitigate an influenza epidemic.员工接种疫苗以减轻流感疫情的计算机模拟。
Am J Prev Med. 2010 Mar;38(3):247-57. doi: 10.1016/j.amepre.2009.11.009. Epub 2009 Dec 30.
4
Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.接种 2009 年大流行性流感（H1N1）疫苗的效果和成本效益。
Ann Intern Med. 2009 Dec 15;151(12):829-39. doi: 10.7326/0003-4819-151-12-200912150-00157.
5
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.在结合疫苗时代，侵袭性肺炎球菌病的持续减少。
J Infect Dis. 2010 Jan 1;201(1):32-41. doi: 10.1086/648593.
6
Pneumococcal polysaccharide vaccine: cost-effectiveness recommendations in adults.肺炎球菌多糖疫苗：成人的成本效益推荐意见。
Expert Rev Pharmacoecon Outcomes Res. 2005 Oct;5(5):541-51. doi: 10.1586/14737167.5.5.541.
7
The timing of influenza vaccination for older adults (65 years and older).老年人（65 岁及以上）流感疫苗接种的时间。
Vaccine. 2009 Nov 23;27(50):7110-5. doi: 10.1016/j.vaccine.2009.09.056. Epub 2009 Sep 26.
8
What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?现代医学的价值对于每质量调整生命年5万美元的决策规则有何看法？
Med Care. 2008 Apr;46(4):349-56. doi: 10.1097/MLR.0b013e31815c31a7.
9
Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.成人肺炎球菌多糖疫苗接种的替代策略：一项成本效益分析。
Vaccine. 2008 Mar 10;26(11):1420-31. doi: 10.1016/j.vaccine.2008.01.007. Epub 2008 Jan 29.
10
Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?肺炎球菌结合疫苗和多糖疫苗的联合接种程序：低反应性是一个问题吗？
Lancet Infect Dis. 2007 Sep;7(9):597-606. doi: 10.1016/S1473-3099(07)70210-4.

50 岁人群中接种双联流感和肺炎球菌疫苗的成本效益分析。

Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.

机构信息

University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

出版信息

Vaccine. 2010 Nov 10;28(48):7620-5. doi: 10.1016/j.vaccine.2010.09.053. Epub 2010 Sep 29.

DOI:10.1016/j.vaccine.2010.09.053
PMID:20887828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2981678/
Abstract

Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.

摘要

流感疫苗接种现推荐用于所有年龄段；美国疾病预防控制中心（CDC）的肺炎球菌多糖疫苗（PPV）接种建议是基于非老年患者的合并症制定的。我们构建了一个马尔可夫模型，以评估对 50 岁人群同时进行流感和肺炎球菌疫苗接种的成本效益。患者随访 10 年，敏感性分析中还考察了不同的时间范围。在 100%疫苗接种率的情况下，与 CDC 推荐方案相比，双重疫苗接种的成本为每 QALY 增加 37700 美元；在观察到的疫苗接种率下，双重疫苗接种的成本为每 QALY 增加 5300 美元。结果对较短的时间范围较为敏感，更倾向于 CDC 的推荐方案。我们发现对所有 50 岁人群进行双重疫苗接种在经济上是合理的。持续时间较短的模型可能无法充分体现 PPV 的效果。